Split the pot? Radius shows its osteoporosis cards in final blockbuster match with Amgen
Radius Health $RDUS has taken another big leap down the final stretch of its Phase III race with Amgen $AMGN, posting Phase III results that show abaloparatide’s clear clinical benefit over a placebo in treating osteoporosis. But while the data provide a fresh argument in favor of its near-term approval at the FDA and EMA, there’s still a big question left unanswered: Just how competitive will this drug be against Amgen’s Phase III rival, as well as Eli Lilly’s aging Forteo? And meanwhile, the roll up to the FDA is also lighting a fresh fire under the heated debate over the cost of drugs, both old and new.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
